Indium In-111 satumomab pendetide
Also known as: 111In-satumomab pendetide, CYT-103, In-111 satumomab pendetide, OncoScint, OncoScint CR/OV, Satumomab pendetide
Source Indium In-111 satumomab pendetide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Indium‑111 satumomab pendetide (OncoScint) is a murine Fab' radiopharmaceutical used for diagnostic imaging of TAG‑72‑expressing tumors, primarily colorectal cancer.
Mechanism of Action
Fab' fragment binds TAG-72 antigen on tumor cells; indium‑111 emits gamma photons for scintigraphic imaging.
Routes of Administration
Goals & Uses
- Staging and restaging of adenocarcinomasOncology DiagnosticsLow
- Tumor imagingDiagnosticHigh
- Detection of ovarian carcinomaDiagnostic ImagingModerate
- Detection of extrahepatic colorectal carcinomaDiagnostic ImagingModerate
Contraindications
- Hypersensitivity to murine proteins or prior murine antibody exposureAllergy / ImmunologicHigh
- Known hypersensitivity to murine antibodiesImmuneModerate
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- BreastfeedingPopulationHighPotential transfer into breast milk or insufficient safety data
Adverse Effects
- Radiation exposureRadiologicalCommon
- Human anti-mouse antibody (HAMA) formationImmunologicCommon
- Hypersensitivity / allergic reactionsImmunologicUncommon
- Fever and chillsConstitutionalUncommon
- Infusion reactionImmuneCommon
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
- Radiation‑related transient leukopeniaHematologicRare
Drug Interactions
- Other murine antibody-based agentsHigh
- Concurrent radiopharmaceuticalsModerate
- ImmunosuppressantsLowPotential interaction with immune pathways or infection risk
Population Constraints
- Renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- Patients with prior murine antibody therapyImmunologic HistoryRelative
Regulatory Status
- European UnionUnapprovedNever marketed in EU.
- United StatesWithdrawnApproved: Imaging of TAG‑72‑positive colorectal cancerDiscontinued 2004.
- United KingdomUnapprovedNot authorized.
Approved by the FDA in 1992 for immunoscintigraphy of colorectal and ovarian cancer. Subsequently withdrawn from the US market by the manufacturer (Cytogen Corporation) for commercial reasons, not safety concerns. No longer marketed in the US or EU.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Indium In-111 satumomab pendetide?
Indium‑111 satumomab pendetide (OncoScint) is a murine Fab' radiopharmaceutical used for diagnostic imaging of TAG‑72‑expressing tumors, primarily colorectal cancer.
What is Indium In-111 satumomab pendetide used for?
Indium In-111 satumomab pendetide is educationally associated with: Staging and restaging of adenocarcinomas, Tumor imaging, Detection of ovarian carcinoma, Detection of extrahepatic colorectal carcinoma. Educational only — not medical advice.
How is Indium In-111 satumomab pendetide administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Indium In-111 satumomab pendetide?
Reported adverse effects include: Radiation exposure, Human anti-mouse antibody (HAMA) formation, Hypersensitivity / allergic reactions, Fever and chills, Infusion reaction, Nausea, Radiation‑related transient leukopenia. This list is not exhaustive — consult a qualified clinician.
Who should avoid Indium In-111 satumomab pendetide?
Recorded contraindications: Hypersensitivity to murine proteins or prior murine antibody exposure, Known hypersensitivity to murine antibodies, Pregnancy, Breastfeeding. Consult a qualified clinician before use.